{
    "clinical_study": {
        "@rank": "28517", 
        "arm_group": {
            "arm_group_label": "rituximab infusion", 
            "arm_group_type": "Other", 
            "description": "Every patient is getting the same therapy of rituximab.  If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 20 hours"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the impact of rapid infusion rituximab on the\n      incidence of infusion-related reactions in patients with Autoimmune Diseases."
        }, 
        "brief_title": "Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Autoimmune Diseases", 
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Autoimmune patient at Wake Forest Baptist Health that is eligible for rituximab\n             therapy\n\n          -  Tolerate the standard infusion rituximab with \u2264 grade 2 hypersensitivity reaction\n\n          -  Consent to participate in the rapid infusion study\n\n          -  Age \u2265 18 years \u2264 80 years\n\n        Exclusion Criteria:\n\n          -  Tolerate the standard infusion rituximab with \u2265 grade 3 hypersensitivity reaction\n\n          -  Neurocognitive impairment (i.e. dementia,  Alzheimers, et al)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040116", 
            "org_study_id": "IRB00022197"
        }, 
        "intervention": {
            "arm_group_label": "rituximab infusion", 
            "description": "Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.", 
            "intervention_name": "Rapid Infusion Rituximab", 
            "intervention_type": "Drug", 
            "other_name": "Rituxan"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Rapid Infusion Rituximab", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Wake Forest Baptist Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases", 
        "overall_contact": {
            "email": "epharr@wakehealth.edu", 
            "last_name": "Emily Pharr, MD", 
            "phone": "3367163869"
        }, 
        "overall_official": {
            "affiliation": "Wake Forest Baptist Health", 
            "last_name": "LeAnne D Kennedy, PharmD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients are given therapy on day 1 and if infusion is tolerated with < grade 2 reaction based on the CTCAE v4 then then will proceed to rapid infusion on day 14 which is given over 2 hours. The number and grade of infusion reaction is measured for all 20 patients and in all infusions given.", 
            "measure": "Incidence of infusion related reactions with rapid infusion compared to standard infusion", 
            "safety_issue": "Yes", 
            "time_frame": "up to 24 hours after infusion on Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040116"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wake Forest Baptist Health", 
            "investigator_full_name": "LeAnne Kennedy, PharmD, BCOP, CPP", 
            "investigator_title": "Pharmacy Clinical Specialist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Reduction in chair time with rapid infusion compared to standard infusion", 
            "safety_issue": "No", 
            "time_frame": "up to 24 hours after infusion on day 14"
        }, 
        "source": "Wake Forest Baptist Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wake Forest Baptist Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}